Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
摘要:
The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.
[EN] URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'URACILE COMME INHIBITEURS D'AXL ET C-MET KINASES
申请人:CEPHALON INC
公开号:WO2013074633A1
公开(公告)日:2013-05-23
The present invention provides compounds of Formula I, or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c,Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.
URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
申请人:Ignyta, Inc.
公开号:US20150209358A1
公开(公告)日:2015-07-30
The present application provides compounds of Formula I
or salt forms thereof, wherein R
a
, R
b
, R
c
, R
d
, D, W, R
1a
, R
1b
, R
1c
, Y, R
3
, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.